AASLD2015

Naltrexone/bupropion Improves Liver Enzymes in Obese, Overweight

By November 17, 2015

Treatment with extended release naltrexone/bupropion (NB) for weight loss significantly improved and normalized serum ALT levels in obese and overweight individuals at high risk for non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes, reported Allison Winokur, PhD, from Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, at The Liver Meeting® 2015.

TDF Reduces Perinatal HBV Transmission in Highly Viremic Mothers

By November 17, 2015

Treatment with tenofovir disoproxil fumarate in late pregnancy in highly viremic mothers with hepatitis B virus (HBV) infection effectively reduced mother-to-child transmission, a study reported at The Liver Meeting® 2015.

Are Adult Doses of HCV Regimens Appropriate in Adolescents?

By November 17, 2015

Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofosbuvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection, reported Brian Kirby, PhD, from Gilead Sciences, Foster City, CA, at The Liver Meeting® 2015.

For HBV Patients With Lamivudine Resistance, TDF MonoTx Still Effective

By November 17, 2015

Monotherapy with tenofovir disoproxil fumarate (TDF) was equally effective as combination therapy with emtricitabine/TDF (FTC/TDF) in patients with chronic hepatitis B virus (HBV) infection harboring lamivudine resistance mutations, a study presented at The Liver Meeting® 2015 has found.

Antivirals Benefit Hep B Patients With Normal or Elevated ALT

By November 17, 2015

Antiviral therapy in patients with non-cirrhotic chronic hepatitis B (CHB) and normal to minimally-elevated alanine aminotransferase (ALT) levels significantly reduced the risk of hepatocellular carcinoma, reported Joseph K. Hoang from Stanford University Medical Center, Palo Alto, CA, at The Liver Meeting® 2015.

Sofosbuvir-Based Therapy Leads to Rapid LOXL2 Decline in Cirrhosis

By November 17, 2015

A rapid decline in serum/plasma lysyl oxidase-like-2 (LOXL2) levels was seen in cirrhotic patients treated with sofosbuvir (SOF)-based therapy, reported authors of a new study presented at The Liver Meting® 2015.

Statins Users Have Lower Risk of Developing HCC, Study Finds

By November 17, 2015

Statin use and liver cancer were independently associated with older age, race, higher prevalence of diabetes, liver cirrhosis, smoking, BMI, and more total healthcare utilization, a study reported at The Liver Meeting® 2015.

Hep C Eradication Triggers Significant Lipid, Glucose Changes

By November 17, 2015

The benefits of eradicating hepatitis C virus (HCV) infection with sofosbuvir may go well beyond avoiding the damage caused by chronic liver inflammation, to include declines in glycated hemoglobin (HbA1c) and other metabolic parameters, according to a study reported at The Liver Meeting® 2015.

For HBV Patients With Low Viral Load, Combo Therapy Better Than None

By November 17, 2015

Combination treatment with peginterferon alfa-2a (peg-IFN) and adefovir or tenofovir for 48 weeks results in a loss and greater decline in HBsAg compared to no treatment in chronic hepatitis B (CHB) patients with a low viral load (LVL), reported Annikki de Niet, MD, from Academic Medical Center, Amsterdam, Netherlands, at The Liver Meeting® 2015.

Sustained HBV DNA Undetectability With Entecavir Monotherapy

By November 17, 2015

New data reported at The Liver Meeting® 2015 indicate that entecavir monotherapy without hepatitis B immune globulin (HBIG) effectively prevents graft loss and death from recurrent hepatitis B after liver transplantation in patients with chronic hepatitis B without prior drug resistant mutations.

Coffee May Reduce the Risk of Alcoholic Hepatitis in Heavy Drinkers

By November 17, 2015

Drinking coffee might reduce the risk of alcoholic hepatitis (AH) among heavy alcohol drinkers, according to a study reported at The Liver Meeting® 2015

PegIFN alfa-2b Non-Inferior to PegIFN alfa-2a in CHB

By November 17, 2015

Peginterferon alfa-2b (Pegberon) demonstrates non-inferior efficacy to peginterferon alfa-2a (PEG IFNα-2a) for the treatment of Chinese HBeAg-positive chronic hepatitis B (CHB) patients, reported Gui-Qiang Wang, MD, PhD, from Peking University First Hospital, Beijing, China, at The Liver Meeting® 2015.

Biomarkers Detect Early Renal Toxicity from NA Monotherapy Post-Transplant

By November 17, 2015

Early biomarkers cystatin C and NGAL may facilitate the safe delivery of long-term nucleos(t)ide analogue (NA) therapy for patients who have undergone liver transplantation, according to a study reported at the The Liver Meeting® 2015.

Does Antiplatelet Therapy Cut Liver Cancer Risk in Patients with Hep B?

By November 17, 2015

Aspirin and clopidogrel therapy are associated with reduced risk of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B infection, according to a study reported at the The Liver Meeting® 2015.

Once-Daily Dual DAA Combo: 97% SVR12 in HCV GT1

By November 16, 2015

The combination of two next-generation direct-acting antiviral (DAA) agents, ABT-493 and ABT-530, was "well tolerated," with all non-cirrhotic patients with hepatitis C virus (HCV) genotype 1 (GT1) infection who completed the 8-week treatment period achieving sustained virologic response at 12 weeks (SVR12), a study presented at The Liver Meeting 2015® has found.

Nutritional Therapy Ups Liver Function in Minimal Hepatic Encephalopathy

By November 16, 2015

In patients with minimal hepatic encephalopathy, nutritional therapy is effective and improves HRQOL, a randomized controlled trial presented during The Liver Meeting® 2015 has reported.

Risk Factors for Portal Vein Thrombosis Identified

By November 16, 2015

Portal vein thrombosis, a complication of cirrhosis, has an annual incidence of 4% in Spain, with risk factors being use of beta-blockers and hepatic encephalopsy, investigators reported during The Liver Meeting® 2015.

Sofosbuvir + Ribavirin Effective in HCV Genotypes 2 and 3

By November 16, 2015

Oral combination sofosbuvir (SOF) and ribavirin (RBV) therapy is "efficacious and well-tolerated" among patients with hepatitis C virus (HCV) genotype 2 or genotype 3 infection, confirmed authors of a study presented at the The Liver Meeting® 2015.

TDF Monotherapy Effective as TDF-Based Combo Therapy in HBV

By November 16, 2015

Patients with chronic hepatitis B virus (HBV) treated with tenofovir rescue monotherapy achieve antiviral efficacy rates similar to those of tenofovir-based combination rescue therapy, even in patients with multi-drug resistance, investigators reported during The Liver Meeting® 2015.

Impact of Renal Function on the 3D Regimen for HCV GT1 Infection

By November 16, 2015

Mild or moderate renal impairment did not impact direct-acting antivirals (DAA) and ritonavir (RTV) exposures, a study presented at The Liver Meeting® 2015 found.

Activity, Work Impairment Scores Improved With 3D Regimens in HCV GT1

By November 16, 2015

Interferon-free ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin showed a more favorable Work Productivity and Activity Impairment (WPAI) profile in treatment-naïve, non-cirrhotic, HCV GT1-infected patients vs. telaprevir + peginterferon/ribavirin (TPV + pegIFN/RBV), reported Yan Liu, MD, PhD, from AbbVie, North Chicago, IL at The Liver Meeting® 2015.

Combo HCV Tx Efficacy Comparable in Elderly, Non-Elderly

By November 16, 2015

At The Liver Meeting® 2015, researchers reported that the efficacy of dual oral therapy with asunaprevir + daclatasvir was comparable between elderly and non-elderly patients with chronic hepatitis C, including compensated cirrhosis.

Impact of Immunosuppressants on HCV SVR in Post-Transplant Patients

By November 16, 2015

Tania M. Welzel, MD, of the Department of Medicine, JW Goethe University Hospital in Frankfurt am Main, Germany, reported, "Among liver transplant recipients treated with LDV/SOF + RBV, similar rapid declines in HCV RNA were observed irrespective of whether patients received CyA or TAC for immunosuppression," at The Liver Meeting® 2015.

Fewer Medical Events Seen with Daclatasvir/Sofosbuvir in HCV GT3 Model

By November 16, 2015

When all patients with hepatitis C virus (HCV) with genotype 3 (GT3) infection are treated with daclatasvir/sofosbuvir, substantially fewer medical events and lower medical costs are accrued" vs. scenarios in which no one is treated or treatment is limited to F3/F4 patients, results of a study using a Markov model presented at The Liver Meeting® 2015 concluded.

Partial HBV Response to Entecavir Still Tied to Favorable Outcomes

By November 16, 2015

Partial virological response to entecavir does not affect long-term clinical outcome in patients with chronic hepatitis B virus (HBV) infection, according to a study presented at The Liver Meeting® 2015.

Ledipasvir/Sofosbuvir: 99% SVR in Asian Patients With HCV GT1

By November 16, 2015

Ledipasvir/sofosbuvir given once daily for 12 weeks was highly effective in Asian patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with compensated cirrhosis, a study concluded at The Liver Meeting® 2015.

3D + R Lowers Liver Morbidity, Mortality Risks in HCV GT1 Post-Transplant

By November 16, 2015

Patients with recurrent hepatitis C virus (HCV) genotype 1 (GT1) infection treated with the "3D+R" regimen post-transplant have a substantially lower likelihood of experiencing compensated or decompensated cirrhosis and death compared with the standard of care, 48 weeks of pegylated interferon plus ribavirin, or no treatment, a study reported at The Liver Meeting® 2015.

RA, Psoriasis Meds May Up Risk of Hep B Flares

By November 16, 2015

Biologic agents are associated with "significantly higher" risk of hepatitis B virus (HBV) flares than non-biologic disease-modifying antirheumatic drugs (nbDMARDs) among patients with rheumatoid arthritis (RA) or psoriasis, according to a study reported at The Liver Meeting® 2015.

Lactulose Improves QoL in Patients with Minimal Hepatic Encephalopathy

By November 16, 2015

In patients with minimal hepatic encephalopathy, prophylactic lactulose treatment improves cognition, quality of life, and intestinal microbiota, results of a multicenter, randomized, controlled trial presented at The Liver Meeting® 2015 have shown.

High SVR12 With Ledipasvir/Sofosbuvir + Ribavirin Despite Transplant Status

By November 16, 2015

Ledipasvir/sofosbuvir with ribavirin treatment for 12 or 24 weeks in patients with decompensated cirrhosis or recurrent hepatitis C virus (HCV) was effective, with low relapse rates, Edward J. Gane, MBChB, MD, from the University of Auckland, Auckland, New Zealand, presented at The Liver Meeting® 2015.